Abstract
In a patient with permanent neonatal syndromic diabetes clinically similar to cases with ONECUT1 biallelic mutations, we identified a disease-causing deletion located upstream of ONECUT1. Through genetic, genomic and functional studies we identified a crucial regulatory region acting as an enhancer of ONECUT1 specifically during pancreatic development. This enhancer region contains a low-frequency variant showing strong association with type 2 diabetes and other glycemic traits, thus extending the contribution of this region to common forms of diabetes. Clinical relevance is provided by experimentally tailored therapy options for patients carrying ONECUT1 coding or regulatory mutations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
S.M. and S.H. are supported by DFG grant HE 7277/3-1 and the Medical Scientist Program at Ulm University awarded to S.H. This project was also funded by an ANR-DFG collaborative research project (grant no. ANR-18-CE92-0031, DFG KL 2544/5-1) to C.J and A.K, and by the European Foundation for the Study of Diabetes/JDRF/Novo Nordisk, the Assistance Publique-Hopitaux de Paris Programme Hospitalier de Recherche Clinique (project DIAGENE) and France Genomique (project DIAPED) to C.J. The CNRGH sequencing platform was supported by the France Genomique National infrastructure, funded as part of the Investissements d Avenir program managed by the Agence Nationale pour la Recherche (contract ANR-10-INBS-09). CD is a scholar of the DFG-funded SFB1074 (project B10N).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Montreal (Centre Hospitalier Universitaire Sainte-Justine) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.